Paracelsus Medizinische Privatuniversitaet Salzburg
- Address
- lock Available on a paid plan
Langerhans Cell Histiocytosis Research
The pediatric department is conducting trials on Langerhans Cell Histiocytosis to lower mortality and prevent disease reactivation in children with multi‑system involvement.
- Early switch to salvage treatment for patients with risk‑organ disease who do not respond to first‑line therapy
- Prolonged continuation therapy (6 vs 12 months) to reduce reactivations in single‑system disease with CNS‑risk or multifocal bone lesions
- Second‑line regimen using prednisone, ara‑C and vincristine followed by maintenance with indomethacin versus 6‑MP/MTX
- Randomized evaluation of therapy intensification to lessen late sequelae
The Department of Pediatric Hematology/Oncology at Paracelsus Medizinische Privatuniversitaet Salzburg leads these studies, aiming to improve long‑term outcomes for children with this rare neoplasm.
Adjuvant Immunotherapy in Resected Melanoma
A trial is comparing a fixed‑dose combination of nivolumab and relatlimab with nivolumab alone to enhance recurrence‑free survival after complete resection of stage III/IV melanoma.
- Assessment of recurrence‑free survival as the primary efficacy endpoint
- Evaluation of the fixed‑dose combination therapy versus monotherapy
- Inclusion of patients with completely resected stage III or IV disease and no evidence of disease
- Investigation of immune‑checkpoint blockade to reduce the risk of melanoma relapse
Conducted by the same pediatric oncology team, this study reflects the site’s broader focus on innovative cancer treatments within the Neoplasms therapeutic area.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Leo Pharma A/S1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 152 other sites in Austria
Therapeutic Area Benchmark — Austria
Select a therapeutic area to compare against other sites in Austria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Austria
Market Share
Country: Austria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Paracelsus Medizinische Privatuniversitaet Salzburg
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Cladribine-Based Regimen in Pediatric and Adolescent Langerhans Cell Histiocytosis: A Randomized, Multicenter Clinical Trial | St. Anna Childrens Cancer Research Institute GmbH | Phase IV | Not Recruiting | Oct 2024 | — |
IMP list
lock Showing 1 of 15 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Alemtuzumab | 1 | Unknown | 2024-10-09 | 2024-10-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.